ADAR1: from basic mechanisms to inhibitors
Trends in Cell Biology · 2025-01 · 35 (1) · 59-73
DOI: 10.1016/j.tcb.2024.06.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cell Biology, 2025-01. Verfasst von Jan Rehwinkel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Departme…. Hauptthemen laut MEDLINE: Adenosine Deaminase, Immunity, Innate, RNA-Binding Proteins. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aimmune Therapeutics, UKRI Medical Research Council.
Abstract (Originalsprache)
Adenosine deaminase acting on RNA 1 (ADAR1) converts adenosine to inosine in double-stranded RNA (dsRNA) molecules, a process known as A-to-I editing. ADAR1 deficiency in humans and mice results in profound inflammatory diseases characterised by the spontaneous induction of innate immunity. In cells lacking ADAR1, unedited RNAs activate RNA sensors. These include melanoma differentiation-associated gene 5 (MDA5) that induces the expression of cytokines, particularly type I interferons (IFNs), protein kinase R (PKR), oligoadenylate synthase (OAS), and Z-DNA/RNA binding protein 1 (ZBP1). Immunogenic RNAs 'defused' by ADAR1 may include transcripts from repetitive elements and other long duplex RNAs. Here, we review these recent fundamental discoveries and discuss implications for human diseases. Some tumours depend on ADAR1 to escape immune surveillance, opening the possibility of unleashing anticancer therapies with ADAR1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK. Electronic a…
- Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK. Electronic address: parinaz.mehdipour@ludw…
Förderung
- Aimmune Therapeutics
- UKRI Medical Research Council
Zitieren
APA
Rehwinkel, J., & Mehdipour, P. (2025). ADAR1: from basic mechanisms to inhibitors. Trends in Cell Biology, 35(1), 59-73. https://doi.org/10.1016/j.tcb.2024.06.006
Vancouver
Rehwinkel J, Mehdipour P. ADAR1: from basic mechanisms to inhibitors. Trends in Cell Biology. 2025;35(1):59-73. doi:10.1016/j.tcb.2024.06.006
BibTeX
@article{Rehwinkel2025,
author = {Rehwinkel, Jan and Mehdipour, Parinaz},
title = {ADAR1: from basic mechanisms to inhibitors},
journal = {Trends in Cell Biology},
year = {2025},
volume = {35},
number = {1},
pages = {59--73},
doi = {10.1016/j.tcb.2024.06.006}
}
EUVIMED